Sarcoglycans and integrins in bisphosphonate treatment: Immunohistochemical and scanning electron microscopy study

De Ponte,Francesco   Saverio; Favaloro,Angelo; Siniscalchi,Enrico  Nastro; Centofanti,Antonio; Runci,Michele; Cutroneo,Giuseppina; Catalfamo,Luciano

doi:10.3892/or.2013.2766

Sarcoglycans and integrins in bisphosphonate treatment: Immunohistochemical and scanning electron microscopy study

Authors:
- Francesco Saverio De Ponte
- Angelo Favaloro
- Enrico Nastro Siniscalchi
- Antonio Centofanti
- Michele Runci
- Giuseppina Cutroneo
- Luciano Catalfamo
View Affiliations

Affiliations: Department of Experimental Medical, Surgical and Odontostomatological Sciences, University of Messina, Messina, Italy, Department of Biomedical Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy
Published online on: October 1, 2013 https://doi.org/10.3892/or.2013.2766
Pages: 2639-2646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment. Bisphosphonates are used in conjunction with antineoplastic chemotherapy for the treatment of hypercalcaemia associated with malignancy, lytic bone metastasis and multiple myeloma. However, it is not known if the osteonecrosis of the jaw lesion originates in the bone or whether it initiates in the gingival epithelium. Two bisphosphonates are commonly used in cancer treatment. One of these is pamidronate disodium, a second-generation bisphosphonate that differs from the first-generation drug because it inhibits bone resorption at a dose that does not affect bone mineralization. The other widely used BP, zoledronate, is a third-generation drug that is the most potent bisphosphonate in clinical use, showing strong anti-osteoclastic activity, similar to pamidronate. The aim of the present study was to evaluate the modifications of human oral mucosa and underlying bone in patients after treatment with these nitrogen-containing bisphosphonates for 24 and 36 months. We analyzed the structural damage of the oral mucosa and damage of the perilesional mandibular bone observing possible correlations from them. Our results allow to express two hypotheses about the mechanism responsible for these results relating to mandible matrix necrosis; first, an increased skeletal microdamage associated with turnover suppression occurred early in treatment and progress with longer treatment duration, second, opening damage in osteonecrosis of the jaw modifies structural morphology of gingival epithelium.

View Figures

View References

1	Merigo E, Manfredi M, Meleti M, et al: Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 77:109–117. 2006.PubMed/NCBI
2	Gutta R and Louis PJ: Methemoglobinemia: an unusual cause of intraoperative hypoxya. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 103:197–202. 2007. View Article : Google Scholar : PubMed/NCBI
3	Fleisch H: The use of bisphosphonates in osteoporosis. Br J Clin Pract. 48:323–326. 1994.PubMed/NCBI
4	Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC and Chen HS: The effect of Alendronate on bone mineral density in the distal part of the femur and the proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am. 85:2121–2126. 2003.PubMed/NCBI
5	Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P and Pini Prato G: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonate treatment. J Clin Periodontol. 32:1123–1128. 2005. View Article : Google Scholar : PubMed/NCBI
6	Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidermic. J Oral Maxillofac Surg. 61:1115–1157. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 62:527–534. 2004. View Article : Google Scholar : PubMed/NCBI
8	Marx RE, Sawatari Y, Fortin M and Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63:1567–1575. 2005. View Article : Google Scholar : PubMed/NCBI
9	Wood J, Bonjean K, Ruetz S, et al: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
10	Santini D, Vincenzi B, Dicuonzo G, et al: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 9:2893–2897. 2003.PubMed/NCBI
11	Nastro Siniscalchi E, Cutroneo G, Catalfamo L, et al: Immunohistochemical evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Oncol Rep. 24:129–134. 2010.PubMed/NCBI
12	Woo SB, Hellstein JW and Kalmar JR: Narrative (corrected) review: BPs and osteonecrosis of the jaws. Ann Intern Med. 144:753–761. 2006.PubMed/NCBI
13	Mehrotra B and Ruggiero S: Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program. 515:356–360. 2006. View Article : Google Scholar : PubMed/NCBI
14	Migliorati CA, Casiglia J, Epsten J, Jacobsen PL, Siegel MA and Woo SB: Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 136:1658–1668. 2005. View Article : Google Scholar : PubMed/NCBI
15	Khosla S, Burr D, Cauley J, et al: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 22:1479–1489. 2007. View Article : Google Scholar : PubMed/NCBI
16	Cheng A, Mavrokokki A, Carter G, et al: The dental implications of bisphosphonates and bone disease. Aust Dent J. 50:S4–S13. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kapitola J and Zák J: Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res. 47:237–240. 1998.PubMed/NCBI
18	Allegra A, Oteri G, Nastro E, et al: Patients with bisphosphonate-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol. 25:164–169. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hellstein JW and Marek CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 63:682–689. 2005. View Article : Google Scholar : PubMed/NCBI
20	Idris AI: Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News Perspect. 21:533–540. 2008.PubMed/NCBI
21	Iwata K, Li J, Follet H, Phipps RJ and Burr DB: Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone. 39:1053–1058. 2006. View Article : Google Scholar : PubMed/NCBI
22	Tobias JH, Chow JW and Chambers TJ: 3-Amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone. Bone. 14:619–623. 1993. View Article : Google Scholar : PubMed/NCBI
23	Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 98:665–672. 1997. View Article : Google Scholar : PubMed/NCBI
24	van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW and Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 33:805–811. 2003.PubMed/NCBI
25	Bauss F and Bergström B: Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment. Curr Clin Pharmacol. 3:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
26	Reid IR, Bolland MJ and Grey AB: Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 41:318–320. 2007. View Article : Google Scholar : PubMed/NCBI
27	Twiss IM, de Water R, den Hartigh J, et al: Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 83:699–703. 1994. View Article : Google Scholar : PubMed/NCBI
28	Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ and Rogers MJ: Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 29:336–343. 2001. View Article : Google Scholar
29	Twiss IM, Pas O, Rampkoopmanscap W, den Harigh J and Vermeij P: The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res. 14:784–791. 1999. View Article : Google Scholar : PubMed/NCBI
30	Landesberg R, Cozin M, Cremers S, Woo V, Koustent S and Sinba S: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 66:839–847. 2008. View Article : Google Scholar : PubMed/NCBI
31	Anastasi G, Amato A, Tarone G, et al: Distribution and localization of vinculin-talin integrin system and dystrophin-glycoprotein complex in human skeletal muscle: immunohistochemical study using confocal laser scanning microscopy. Cells Tissues Organs. 175:151–164. 2003. View Article : Google Scholar
32	Anastasi G, Cutroneo G, Rizzo G, et al: Sarcoglycan and integrin behavior in normal human skeletal muscle: a CLSM (confocal laser scanning microscope) study. Eur J Histochem. 48:245–252. 2004.PubMed/NCBI
33	Anastasi G, Cutroneo G, Santoro G, et al: Integrins, muscle agrin and sarcoglycans during muscular inactivity conditions: an immunohistochemical study. Eur J Histochem. 50:327–336. 2006.PubMed/NCBI
34	Anastasi G, Cutroneo G, Santoro G, et al: Costameric proteins in human skeletal muscle during muscular inactivity. J Anat. 213:284–295. 2008. View Article : Google Scholar : PubMed/NCBI